The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

New, innovative therapies must be added to the existing arsenal of treatments for adult female acne, according to a ...

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...